Sold Out
Book Categories |
Part I Opioid Receptors
1 Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance Lindsay H. Burns Todd W. Vanderah Hoau-Yan Wang 3
2 Upregulation of Opioid Receptors Ellen M. Unterwald Richard D. Howells 19
3 Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders Mark K. Greenwald Caren L. Steinmiller 45
4 Opioid Receptors Antagonist-Mediated Signaling in the Immune System Jonathan Moorman Zhi Qiang Yao Edward J. Bilsky Deling Yin 67
Part II Opioid Antagonists: Chemistry and Pharmacology
5 The Chemistry and Pharmacology of μ-Opioid Antagonists Jean M. Bidlack Jennifer L. Mathews 83
6 Medicinal Chemistry of Kappa Opioid Receptor Antagonists Cecile Beguin Bruce M. Cohen 99
7 The Chemistry and Pharmacology of Delta Opioid Antagonists Beatriz Fioravanti Todd W. Vanderah 119
8 Novel Opioid Antagonists with Mixed/Dual Selectivity Richard B. Rothman Subramaniam Ananthan Edward J. Bilsky 137
9 Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists Ellen A. Walker Sandra D. Comer 153
10 Methylnaltrexone: A Peripherally Acting Opioid Antagonist Chun-Su Yuan Robert J. Israel 175
Part III Substance Abuse
11 Opioid Antagonist Effects in Animal Models Related to Opioid Abuse: Drug Discrimination and Drug Self-Administration S. Stevens Negus 201
12 Naltrexone for Initiation and Maintenance of Opiate Abstinence Kevin A. Sevarino Thomas R. Kosten 227
13 Ultra-Low-Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids Lindsay H. Burns Francesco Leri Mary C. Olmstead 247
14 Can a Combination Formulation Containing a Neutral Opiate Antagonist Decrease the Abuse ofμ-Agonist Opiates John Mendelson Mark Pletcher Gantt Galloway 263
15 Effects of Opioid Antagonists on the Abuse-Related Effects of Psychomotor Stimulants and Nicotine Brenda J. Gehrke Toni S. Shippenberg 273
16 Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence Bernard Le Foll Zuzana Justinova G. Tanda Marcello Solinas Peter Selby Steven R. Goldberg 299
17 Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions Andrea King Rachel Torello Suchitra Krishnan-Sarin Stephanie O'Malley 315
Part IV Alcohol and Ingestive Behaviors
18 Opioid Antagonists and Ethanol's Ability to Reinforce Intake of Alcoholic Beverages: Preclinical Studies Larry D. Reid 335
19 Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence Raymond F. Anton 371
20 Preclinical Effects of Opioid Antagonists on Feeding and Appetite Richard J. Bodnar 387
21 CNS Opiate Systems and Eating Disorders Elliot D. Luby David Koval 407
Part V Behavioral Disorders
22 Potential Utility of Kappa Ligands in the Treatment of Mood Disorders William A. Carlezon Bruce M. Cohen 425
23 Opioid Antagonists in the Treatment of Pathological Gambling and Kleptomania Jon E. Grant 445
24 Efficacy of Opioid Antagonists in Attentuating Self-Injurious Behavior Curt A. Sandman 457
25 Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia Ismene Petrakis 473
Part VI Medical Indications
26 Current Issues in the Use of Opioid Antagonists (Naltrexone for Opiate Abuse: A Re-Educational Tool as Well as an Effective Drug) Colin Brewer Emmanuel Streel 487
27 Emergency Room Use of Opioid Antagonists in Drug Intoxication and Overdose Simon F.J. Clarke Rob Torok Paul I. Dargan Alison L. Jones 511
28 Kappa-Opioid Antagonists as Pruritogenic Agents Alan Cowan Saadet Inan 541
29 Clinical Effect of Opioid Antagonists on Clinical Pruritus Nora V. Bergasa 551
30 Effects of Opioid Antagonists on L-DOPA-Induced Dyskinesia in Parkinson's Disease Susan H. Fox Tom H. Johnston Jonathan M. Brotchie 569
31 Endocrine Effects of Opioid Antagonists Jack H. Mendelson Nancy K. Mello 581
32 Opioid Antagonists in Traumatic Shock: Animal and Human Studies Liangming Liu 605
33 The Efficacy of Opioid Antagonists Against Heatstroke-Induced Ischemia and Injury in Rats Mao-Tsun Lin Ching-Ping Chang Sheng-Hsien Chen 625
34 A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasms Paolo Lissoni 641
35 Nonclinical Pharmacology of VIVITROL®: A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence Reginald L. Dean, III 655
36 The Development of Sustained-Release Naltrexone and Clinical Use in Treating Opiate Dependence Gary K. Hulse Sandra D. Comer Maria A. Sullivan 675
37 The Development of ProNeura Technology for the Treatment of Addictions Lauren C. Costantini 689
38 Development of Opioid Transdermal Delivery Systems Kalpana S. Paudel Stan L. Banks Paul K. Kiptoo Dana C. Hammell R. Reddy Pinninti Caroline Strasinger Audra L. Stinchcomb 709
39 Intranasal Naloxone for Treatment of Opioid Overdose Anne-Maree Kelly Debra Kerr Paul Dietze 729
Index 741
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish ListX
This item is in your CollectionOpiate Receptors and Antagonists: From Bench to Clinic
X
This Item is in Your InventoryOpiate Receptors and Antagonists: From Bench to Clinic
X
You must be logged in to review the productsX
X
X
Add Opiate Receptors and Antagonists: From Bench to Clinic, , Opiate Receptors and Antagonists: From Bench to Clinic to the inventory that you are selling on WonderClubX
X
Add Opiate Receptors and Antagonists: From Bench to Clinic, , Opiate Receptors and Antagonists: From Bench to Clinic to your collection on WonderClub |